Ultragenyx (RARE) Q3 2026 earnings review
Ultragenyx wins two gene-therapy approvals, but scraps its Angelman drug
Ultragenyx won approval for its first two gene therapies while shutting down its two biggest clinical trials. Revenue rose 8% as Evkeeza and Dojolvi made up for a dip in Latin American Crysvita orders, and lower research spending cut quarterly cash burn to $43 million. Chief executive Emil D. Kakkis launched a 20% staff cut after ending the Angelman and Wilson disease programs, while selling two regulatory vouchers for about $350 million in net cash.
| Total revenue | $173M +8% from a year ago |
|---|---|
| Expected net cash from voucher sales | $350M $401M cash on hand at Q3 end |
| 2027 R&D and SG&A ceiling | <$725M cut from <$934M previously by our math |
| Full-year 2026 revenue outlook | Unchanged $730M–$760M (excludes new launches) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because solving the near-term cash crunch came at the cost of the company's main pipeline driver. The good news: winning FDA approval for Genglycos and Fayuvi unlocked $350 million in voucher proceeds and allowed a $209 million deeper cut to the 2027 spending ceiling by our math. The bad news: winding down all studies for GTX-102 in Angelman syndrome wipes out the company's largest potential product.
The question now is whether the smaller commercial business can earn a durable profit in 2027 and beyond without one-time voucher gains. Optimists see two high-priced gene-therapy launches and a much lower cost base carrying the company past break-even; skeptics note that non-cash royalty interest and manufacturing costs still leave a wide gap before OMERS takes a bigger cut of Crysvita royalties in 2028. Formal 2027 revenue targets on the fourth-quarter report will settle it.
🐂 Bull Case
Gene-Therapy Approvals Unlock $350M in Net Voucher Cash
Ultragenyx develops treatments for rare genetic diseases and needed regulatory approvals to fund its operations without selling stock. It cleared both hurdles when the Food and Drug Administration approved Genglycos, a gene therapy for a metabolic disorder called glycogen storage disease type Ia, and Fayuvi, a gene therapy for a childhood neurological condition called Sanfilippo syndrome type A.
Each approval came with a Priority Review Voucher (PRV), a transferable ticket for a faster FDA review that drugmakers can sell. In October the rare-disease drugmaker agreed to sell both vouchers for $413 million in total, which will bring in about $350 million in net cash this quarter. By our math, adding that cash to the $401 million on hand at September 30 lifts its cash reserve to about $751 million, above where it started the year.
What to watch: the closing of the $203 million Fayuvi voucher sale in November and first commercial sales from both gene therapies in the fourth quarter. A smooth close removes the need to sell shares or future royalties to fund 2027 operations.
Evkeeza and Dojolvi Offset a Dip in Crysvita
Crysvita, a medicine for a rare bone disease that brings in nearly two-thirds of total revenue, suffers from uneven bulk ordering in Latin America. Its product sales in Latin America and Türkiye fell 12.8% from a year ago to $41 million in the third quarter, pulling total Crysvita revenue down 2.7% to $109 million, a result the company called "consistent with expected ordering patterns".
- Dojolvi (for fatty acid oxidation disorders): $30 million, up 25.0% from a year ago
- Evkeeza (for severe high cholesterol outside the US): $24 million, up 41.2% from a year ago
- Mepsevii (for a rare enzyme disorder): $10 million, up 42.9% from a year ago
Those three smaller medicines grew fast enough to lift total revenue 8.1% from a year ago to $173 million. Management kept its full-year revenue plans unchanged across the board, which by our math leaves fourth-quarter Crysvita sales growing about 4.8% at the middle of the range.
What to watch: fourth-quarter Crysvita product sales in Latin America against last year's $40 million base. Hitting the $500 million to $520 million full-year target requires at least $142 million of total Crysvita revenue in the final quarter.
🐻 Bear Case
Ultragenyx Ends Its Angelman and Wilson Disease Trials
GTX-102, an experimental treatment for the neurogenetic disorder Angelman syndrome, was the company's biggest late-stage pipeline bet, with pivotal Phase 3 data expected in September or October. Instead of reporting positive trial results, Ultragenyx buried a single bullet point under its cost-cutting plan: "Completing wind-down of all ongoing studies for GTX-102 for Angelman syndrome".
In the same release, the drugmaker announced it is "Terminating UX701 for Wilson disease based on not achieving study goals" after fourth-cohort data failed to show that a majority of patients could stop standard therapy. Losing both programs wipes out two of its major clinical growth drivers and leaves only DTX301, a gene therapy for a metabolic liver disorder with data due in the first half of 2027, and UX143, a bone-disease antibody whose two Phase 3 trials already missed their main goals.
What to watch: any detailed disclosure on the GTX-102 Phase 3 Aspire trial results on the conference call or in the quarterly filing. Stopping all studies means the program will contribute zero future revenue.
The 2027 Profit Target Still Needs Deeper Cuts
"With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward," chief executive Emil D. Kakkis said. Research and development fell 46.0 percentage points of revenue from a year ago to 89.0% in the third quarter, while selling, general and administrative costs rose 1.7 points to 56.1%.
- New 2027 expense ceilings: under $350 million for R&D and under $375 million for SG&A ($725 million combined)
- Nine-month cost of sales: $96 million (18.4% of revenue), plus $63 million of non-cash royalty interest
- 2026 base revenue outlook: $730 million to $760 million, before new launches
By our math, even if Ultragenyx hits the $725 million ceiling for research and overhead, adding ~18% cost of sales and ~80 million of annual non-cash interest on sold royalties puts total 2027 costs well above $950 million. Unless the two new gene therapies bring in well over $100 million in their first full year, reaching full-year accounting profit in 2027 will depend on the one-time gain from the Fayuvi voucher sale or cuts well below the new ceilings.
What to watch: formal 2027 revenue and operating expense targets on the fourth-quarter report. Those numbers will show whether 2027 profit holds up without one-time voucher gains before OMERS takes another 25% of North American Crysvita royalties in January 2028.
👓 Other Themes
20% Headcount Cut and Lower 2027 Spending Ceilings
Following the pipeline failures and gene-therapy approvals, Ultragenyx launched its second restructuring of 2026 to cut about 20% of its staff, leaving roughly 1,000 employees by year-end. The drugmaker will book about $25 million in fourth-quarter severance and restructuring charges, on top of $30 million taken in the first quarter, and plans to shrink its real estate footprint.
💲 Other KPIs
Operating cash burn fell by more than half from $97 million last quarter and $91 million a year ago. Lower research spending drove the improvement, bringing nine-month operating cash use to $337 million against $366 million at this point in 2025.
Working capital — short-term assets minus short-term liabilities — shrank by $100 million in the quarter and is down 72.7% from $567 million at the end of 2025. The $350 million in net cash arriving from the two voucher sales in the fourth quarter will rebuild this buffer.
The average share count rose 2.3% from 99.8 million a year ago and edged up from 101.9 million in the second quarter. Employee stock-based compensation of $34 million in the quarter ($98 million over nine months) continues to add shares gradually.
🔮 Guidance
Unchanged. The plan still calls for 10.7% growth at the middle of the range, excluding any fourth-quarter sales from Genglycos and Fayuvi. By our math, that leaves $207 million to $237 million for the fourth quarter, or 7.2% growth at the middle of the range against a tough $207 million comparison a year ago.
Unchanged. Management kept the full-year target at 6.0% growth at the middle of the range. After $358 million in the first nine months, the outlook implies $142 million to $162 million in the fourth quarter by our math, or 4.8% growth at the middle of the range.
Unchanged. The full-year plan points to 9.4% growth at the middle of the range. With $75 million already booked in the first nine months, by our math the middle of the range leaves $30 million for the fourth quarter, flat against the third quarter and down 6.3% from a year ago.
Tightened. Winding down the Angelman and Wilson disease trials and cutting 20% of the workforce lowers the 2027 combined research and overhead ceiling to under $725 million, down 22.4% from the prior $934 million cap by our math. The new R&D ceiling is at least 53.3% below 2025's $750 million spend.
Unchanged, with the accounting basis restored. The drugmaker returned to promising "full-year GAAP profitability in 2027 and going forward" after several quarters of saying only "profitability", backed by deeper cost cuts and two commercial gene-therapy launches.
❓ Key Questions
Why did Ultragenyx wind down all GTX-102 Angelman studies?
Phase 3 Aspire top-line data were due in September or October, yet the release announced a complete wind-down of all GTX-102 studies in one bullet point without giving the trial numbers or saying whether the study missed its main goal.
Does 2027 GAAP profitability rely on one-time voucher gains?
Even if research and overhead sit near the $725 million ceiling, adding cost of sales and ~$80 million in non-cash royalty interest pushes total expenses past $950 million, so investors need to know if 2027 operating profit is positive without voucher sales.
How many patients have started on Genglycos and Fayuvi?
Chief executive Emil D. Kakkis said the two gene-therapy launches are "progressing well with growing demand", but the release excluded launch sales from the 2026 outlook and gave no patient start forms or treatment-center counts.
What did regulators say about UX143 requires another trial?
The company presented new analyses from its two failed Phase 3 bone-disease studies and is talking to regulators about a filing path, which will decide whether UX143 gets written off or requires more trial spending.